Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436500 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01436500 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT01436500, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
Interventions
- DRUG Placebo
- DRUG Ifetroban Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436500
The ClinicalTrials.gov registry entry for NCT01436500 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01436500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01436500 about?
NCT01436500 is a clinical study titled "Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients". A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
What is the current status of trial NCT01436500?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2011-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01436500?
The interventions under investigation include: Placebo (DRUG), Ifetroban Injection (DRUG).
Who is sponsoring clinical trial NCT01436500?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.